Current Report Filing (8-k)
September 02 2016 - 7:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 30, 2016
ALDEYRA THERAPEUTICS, INC.
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36332
|
|
20-1968197
|
(State or other Jurisdiction
of Incorporation)
|
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
131 Hartwell Avenue, Suite 320
Lexington, MA 02421
(Address of principal executive offices and zip code)
Registrants telephone number, including area code: (781) 761-4904
Not Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
(b) On August 30, 2016, Aldeyra Therapeutics, Inc. (Aldeyra) and Scott L. Young agreed that Mr. Young would step down from his position
as Chief Operating Officer of Aldeyra effective August 30, 2016.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
ALDEYRA THERAPEUTICS, INC.
|
|
|
By:
|
|
/s/ Todd C. Brady, M.D., Ph.D.
|
|
|
Name:
|
|
Todd C. Brady, M.D., Ph.D.
|
|
|
Title:
|
|
President and Chief Executive Officer
|
Dated: September 2, 2016
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Sep 2023 to Sep 2024